Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXOHYH)

Drug Name

Etavopivat Drug Info

Synonyms

Etavopivat; FT-4202; Etavopivat [INN]; Etavopivat [USAN]; 2245053-57-8; V4E0A9M44Q; 1-Propanone, 1-(5-((2,3-dihydro-1,4-dioxino(2,3-b)pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo(3,4-C)pyrrol-2(1H)-yl)-3-hydroxy-2-phenyl-, (2S)-; 1-Propanone, 1-[5-[(2,3-dihydro-1,4-dioxino[2,3-b]pyridin-7-yl)sulfonyl]-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl]-3-hydroxy-2-phenyl-, (2S)-; Etavopivat [USAN:INN]; UNII-V4E0A9M44Q; CHEMBL4650332; SCHEMBL20511240; GTPL11975; GLXC-25164; EX-A6335; FT4202; WHO 11646; AKOS040757470; MS-28351; CS-0213556; (2S)-1-(5-(2,3-Dihydro(1,4)dioxino(2,3-b)pyridine-7- sulfonyl)-3,4,5,6-tetrahydropyrrolo(3,4-C)pyrrol-2(1H)- YL)-3-hydroxy-2-phenylpropan-1-one; (2S)-1-[5-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-ylsulfonyl)-1,3,4,6-tetrahydropyrrolo[3,4-c]pyrrol-2-yl]-3-hydroxy-2-phenylpropan-1-one; (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2/3	[1]

Cross-matching ID

PubChem CID: 135338378
TTD Drug ID: DMXOHYH

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Pyruvate kinase (PK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AGS-348	DMDUIO4	Hereditary angioedema	4A00.14	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Pyruvate kinase (PK)	TTABNSJ	NOUNIPROTAC	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04624659) An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS). U.S.National Institutes of Health.
2	Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380(3):210-219.
3	Clinical pipeline report, company report or official report of Agios Pharmaceuticals.